You are here: HomeNews & Opinions - Headlines › SAFC Wins Commercial Licensing of CHOZN Platform in Asia

SAFC Wins Commercial Licensing of CHOZN Platform in Asia

Jun. 05, 2013

Sigma-Aldrich today announced that SAFC Commercial, its custom manufacturing services business unit, has won commercial sales and licensing contracts with two leading Asian biopharmaceutical companies for the purchase of CHOZN, their off-the-shelf cell line production platform.

The CHOZN Platform consists of the CHOZN GS-/- CHO cell line and an optimized set of cGMP-produced, chemically defined (CD) media and feeds designed specifically for the cell line to maximize the production of monoclonal antibodies and other r-proteins.

 

Related Articles :

Keywords : biopharmaceuticals cell lines cell technology CHO cells CHOZN platform Custom Manufacturing pharmaceutical industry SAFC SAFC Asia SAFC Commercial SAFC licensing contract Sigma Sigma-Aldrich Sigma-Aldrich Asia

RSS Newsletter